Bedaquiline adherence measured by electronic dose monitoring predicts clinical outcomes in the treatment of patients with multidrug-resistant tuberculosis and HIV/AIDS.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of acquired immune deficiency syndromes"
DOI: 10.1097/qai.0000000000002940
Abstract: BACKGROUND Novel regimens have revolutionized multidrug-resistant tuberculosis (MDR-TB) treatment; however, medication adherence remains challenging and poorly characterized. We hypothesized that bedaquiline adherence, measured using electronic dose monitoring, would predict MDR-TB treatment outcomes. SETTING Prospective cohort… read more here.
Keywords: treatment; adherence; bedaquiline adherence; dose monitoring ... See more keywords